Google
PRLD — PRELUDE THERAPEUTICS INC (Healthcare >> Biotechnology)
PRLD FAQ
What is PRLD's ROE?
PRELUDE THERAPEUTICS INC reports a Return on Equity (ROE) of -129.27%.
What is PRLD's dividend yield?
PRELUDE THERAPEUTICS INC offers a dividend yield of 0.00%.
What is PRLD's Deepscope Quality Score?
Deepscope rates PRLD's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PRLD?
Deepscope's AI Timing Score for PRLD is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PRLD belong to?
PRELUDE THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.81
Price
-0.27
(-6.62%)
Day Change
|
|
|---|
PRLD, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 71 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.81 |
| PBV / Sector |
5.40 / 4.63
|
| Earning Per Share | -0.91 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
1.40 M
GREAT
|
| Average 1W Daily Value |
1.21 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:07 |
| Symbol | PRLD |
| Name | PRELUDE THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 64.92 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 324.95 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 175 Innovation Boulevard, Wilmington, DE, United States, 19805
Phone: 302 467 1280
Website: https://preludetx.com
Employees: 79
Sector: Healthcare >> Biotechnology
Description: Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
